As of 2025: What is the current market price of tepotinib?

Tepotinib as a targeted therapy drug, is mainly used to treat MET exon 14 skipping mutation (METex14) type non-small cell lung cancer (NSCLC) patients. Due to its high therapeutic effect, its market price is relatively high. In particular, original drugs are usually more expensive due to factors such as research and development costs and market pricing.

In China, the original drug Tepotinib has been included in the medical insurance system, which means that eligible patients can be reimbursed for part of the cost through medical insurance, reducing the financial burden on patients. However, if patients purchase original drugs directly from hospitals, they usually have to pay about more than 30,000 yuan. This is still a significant expense for some patients, especially in the case of long-term treatment, where the cost of treatment can be substantial.

However, with the promotion of tepotinib in the global market, especially the emergence of some generic drugs, the market price has gradually become more reasonable. Several pharmaceutical companies in Laos, such as Big Bear Pharmaceuticals, Lucius Pharmaceuticals and ASEAN Pharmaceuticals, produce generic Tepotinib drugs at significantly lower prices than the original drugs. The therapeutic effects of these generic drugs are basically the same as those of the original drugs, but the price is only about RMB 6,000, which significantly reduces the financial burden on patients. Especially in some developing countries and regions, the price advantage of generic drugs allows more patients to receive this targeted therapy.

It is worth noting that although the price of generic drugs is cheaper, the reliability of their quality and effects has also attracted attention from patients and the medical community. To ensure the safety and effectiveness of treatment, patients should choose reputable manufacturers and use these drugs under the guidance of a doctor.

Reference materials:https://www.tepotinib.com/